Published in Oncogene on July 24, 2003
TIG3: a regulator of type I transglutaminase activity in epidermis. Amino Acids (2008) 0.91
Induction of apoptosis by the retinoid inducible growth regulator RIG1 depends on the NC motif in HtTA cervical cancer cells. BMC Cell Biol (2009) 0.91
Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells. Cell Death Differ (2014) 0.87
TIG3 tumor suppressor-dependent organelle redistribution and apoptosis in skin cancer cells. PLoS One (2011) 0.85
TIG3: an important regulator of keratinocyte proliferation and survival. J Invest Dermatol (2014) 0.82
Decreased expression of type II tumor suppressor gene RARRES3 in tissues of hepatocellular carcinoma and cholangiocarcinoma. World J Gastroenterol (2005) 0.78
RARRES3 suppressed metastasis through suppression of MTDH to regulate epithelial-mesenchymal transition in colorectal cancer. Am J Cancer Res (2015) 0.77
Tazarotene induces apoptosis in human basal cell carcinoma via activation of caspase-8/t-Bid and the reactive oxygen species-dependent mitochondrial pathway. DNA Cell Biol (2014) 0.76
Genome-wide identification of target genes for miR-204 and miR-211 identifies their proliferation stimulatory role in breast cancer cells. Sci Rep (2016) 0.76
RARRES3 regulates signal transduction through post-translational protein modifications. Mol Cell Oncol (2015) 0.75
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res (2003) 4.22
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst (2004) 2.38
Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst (2003) 2.31
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev (2006) 2.22
Focus on head and neck cancer. Cancer Cell (2004) 2.11
International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev (2006) 2.04
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) (2009) 1.99
A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res (2002) 1.87
Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst (2007) 1.79
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst (2003) 1.75
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol (2009) 1.74
Examining the role of mitochondrial respiration in vanilloid-induced apoptosis. J Natl Cancer Inst (2002) 1.71
Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) (2009) 1.71
BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med (2003) 1.67
Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol (2002) 1.66
High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) (2009) 1.59
Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst (2007) 1.58
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) (2009) 1.57
p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J Natl Cancer Inst (2002) 1.56
Mechanisms underlying the induction of the putative human tumor suppressor GPRC5A by retinoic acid. Cancer Biol Ther (2009) 1.54
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) (2011) 1.53
Contrast agents for confocal microscopy: how simple chemicals affect confocal images of normal and cancer cells in suspension. J Biomed Opt (2002) 1.53
Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res (2008) 1.50
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol (2002) 1.50
Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. Cancer Biol Ther (2004) 1.49
Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer (2004) 1.47
Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations. Cancer Biol Ther (2005) 1.47
Vitamin A enhances in vitro Th2 development via retinoid X receptor pathway. J Immunol (2002) 1.44
Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J Biol Chem (2003) 1.43
Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol (2002) 1.41
Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis (2002) 1.39
Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology (2009) 1.39
Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control (2003) 1.39
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res (2003) 1.32
Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res (2004) 1.32
Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res (2009) 1.32
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res (2004) 1.30
Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Mol Cancer Ther (2009) 1.28
XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis (2003) 1.28
Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res (2004) 1.27
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol (2004) 1.25
Programmed cell death is required for palate shelf fusion and is regulated by retinoic acid. Dev Biol (2002) 1.24
Requirement for RAR-mediated gene repression in skeletal progenitor differentiation. J Cell Biol (2002) 1.23
Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors. J Biol Chem (2004) 1.21
Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res (2002) 1.21
A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res (2010) 1.21
Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res (2006) 1.20
Dorsoventral patterning of the Xenopus eye: a collaboration of Retinoid, Hedgehog and FGF receptor signaling. Development (2005) 1.19
Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis (2004) 1.17
Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res (2006) 1.17
A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res (2004) 1.17
Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer (2004) 1.16
Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila) (2010) 1.15
Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. Cancer Res (2005) 1.15
Dietary folate intake and lung cancer risk in former smokers: a case-control analysis. Cancer Epidemiol Biomarkers Prev (2003) 1.12
Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res (2004) 1.11
Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer (2006) 1.11
Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis. Cancer Prev Res (Phila) (2010) 1.11
Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther (2007) 1.11
Evidence that the human death receptor 4 is regulated by activator protein 1. Oncogene (2002) 1.08
A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase. J Biol Chem (2003) 1.08
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res (2004) 1.08
Retinoid x receptor agonists increase bcl2a1 expression and decrease apoptosis of naive T lymphocytes. J Immunol (2005) 1.07
Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor, and liver X receptor in mouse liver. Mol Pharmacol (2004) 1.06
Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res (2006) 1.06
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer (2005) 1.05
GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res (2002) 1.05
Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res (2004) 1.05
Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells. Mol Cancer Ther (2002) 1.04
Mechanism of asymmetric ovarian development in chick embryos. Development (2008) 1.04
Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid X receptors. J Biol Chem (2005) 1.03
Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res (2006) 1.02
Induction of endoplasmic reticulum stress by the pro-apoptotic retinoid N-(4-hydroxyphenyl)retinamide via a reactive oxygen species-dependent mechanism in human head and neck cancer cells. Cancer Biol Ther (2007) 1.02
A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer (2002) 1.01
MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis (2010) 1.01
Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst (2003) 1.00
Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin. Cancer Biol Ther (2005) 1.00
A novel transglutaminase activator forms a complex with type 1 transglutaminase. Oncogene (2005) 1.00
Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res (2006) 1.00
Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J Natl Cancer Inst (2004) 0.99
Multiple points of interaction between retinoic acid and FGF signaling during embryonic axis formation. Development (2004) 0.99
Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo. Clin Cancer Res (2005) 0.99
Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res (2009) 0.99
Decreased expression of retinoid receptors in melanoma: entailment in tumorigenesis and prognosis. Clin Cancer Res (2007) 0.98
Casein kinase 1alpha interacts with retinoid X receptor and interferes with agonist-induced apoptosis. J Biol Chem (2004) 0.97
Safety and efficacy of dose-intensive oral vitamin A in subjects with sun-damaged skin. Clin Cancer Res (2004) 0.97